Precision diagnostics in oncology and transplantation—delivered with purpose, powered by science.
At iMDx, we advance precision medicine through innovative diagnostics that serve the needs of researchers, clinicians, and healthcare systems. Whether enabling early detection, guiding treatment, or accelerating discovery, our solutions are designed to deliver clear, actionable insights that drive better decisions across the continuum of care.
Our molecular diagnostic solutions are built to support decision-making across clinical practice, translational research, and laboratory operations. From transplant monitoring to cancer immunotherapy guidance, we provide accurate, scalable tools that drive discovery, streamline workflows, and enable more informed decisions in both clinical and research settings.
Blood-based transplant monitoring test that quantifies the concentration of donor-derived cell-free DNA (dd-cfDNA) following transplantation
(in development) A clinical assay intended to quantify relative (%) and absolute (cp/mL) levels of donor-derived cell-free DNA (dd-cfDNA) in plasma following kidney transplantation
Research use only blood-based dd-cfDNA test kit that quantifies the concentration of donor-derived cell-free DNA (dd-cfDNA) following transplantation
In-development test that measures genomic copy number instability in circulating tumor DNA to monitor therapeutic efficacy in cancer patients
27-gene expression laboratory developed test that assesses the tumor microenvironment to predict likelihood of response to immunotherapies
Research use only 27- gene expression assay test kit that assesses the tumor microenvironment
Everything we do is shaped by a shared commitment to patients, science, and each other.
At Insight Molecular Diagnostics Inc., (iMDx), we’re investing in a mission to democratize access to molecular diagnostic testing, and helping the healthcare industry deliver upon the promises of precision medicine. Our focus is on transplant and oncology, two of the fastest-growing areas in diagnostics, where better tools can create sustainable long-term value for researchers, clinicians, hospitals, and patients.
We’re innovating beyond designing laboratory tests — we’re building a platform for global accessibility to transformative care.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse vitae...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse vitae...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse vitae...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse vitae...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse vitae...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse vitae...
©2025 Insight Molecular Diagnostics Inc. All rights reserved. iMDx, GraftAssureCore, GraftAssureIQ, GraftAssureDx, DetermaIO, DetermaCNI, and OncoTIME are trademarks of Insight Molecular Diagnostics Inc. All other trademarks are the property of their respective owners. For the intended uses of all products, please refer to www.imdxinc.com.
WEBSITE BY: LEFT HAND DESIGN
iMDx Terms and Conditions of Sale shall govern the sale and purchase of the products quoted herein. Please see Terms and Conditions for additional details.
iMDx Terms and Conditions of Sale shall govern the sale and purchase of the products quoted herein. Please see Terms and Conditions for additional details.
iMDx Terms and Conditions of Sale shall govern the sale and purchase of the products quoted herein. Please see Terms and Conditions for additional details.
iMDx Terms and Conditions of Sale shall govern the sale and purchase of the products quoted herein. Please see Terms and Conditions for additional details.
iMDx Terms and Conditions of Sale shall govern the sale and purchase of the products quoted herein. Please see Terms and Conditions for additional details.
iMDx Terms and Conditions of Sale shall govern the sale and purchase of the products quoted herein. Please see Terms and Conditions for additional details.